Vince & Associates Clinical Research Completes Enrollment of Human Abuse Liability Study for Centanafadine for Adult ADHD

Overland Park, Kansas - Vince & Associates Clinical Research, a premier provider of early phase clinical research services, announced the completion of enrollment of a human abuse liability (HAL) clinical trial of centranafadine (formerly EB-1020). Centranafadine is a novel non-stimulant being developed by Neurovance of Cambridge, MA for the treatment of adult attention deficit hyperactivity disorder (ADHD).

Dr. Brad Vince, CEO and Medical Director of Vince & Associates Clinical Research expressed, "We are excited to be working with Neurovance on this important human abuse liability trial."

Vince & Associates has been highly successful in conducting HAL studies based on their access to a large database of recreational drug users for rapid study enrollment. In addition, the physicians are experienced in the identification of appropriate study subjects for all types of substance abuse studies and have been working with both substance dependent volunteers as well as recreational drug users for many years.

Dr. Vince, further stated, "Our Physician Research Model® is vital when conducting human abuse liability clinical trials either for new chemical entities or abuse deterrent formulations. Our principal investigators are intricately involved in all aspects of each clinical trial ensuring that proper medical and technical procedures are completed to the highest degree of quality."

The Neurovance HAL study is a five-arm clinical study designed to evaluate the abuse potential for centanafadine at two doses among qualified recreational stimulant users when compared with Schedule II comparators d-amphetamine or lisdexamfetamine. The leading products for ADHD are stimulants, which are heavily restricted due to abuse liability.

About Vince & Associates Clinical Research
Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for 15 years. The research professionals at Vince & Associates are proud to be recognized in the industry as a "Center of Research Excellence."

Vince & Associates currently operates a state-of-the-art, multimillion-dollar, 100-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This early development unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short and long-term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theater and game rooms, no detail has been overlooked.

About Altasciences
Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithme Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

More Information
Additional background materials pertaining to Vince & Associates Clinical Research are located on the corporate website at

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.